Clinical Trials Arena on MSN17d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of overall ...
pharmaphorum5d
NICE turns down Enhertu in “devastating” move, says charity
AstraZeneca and Daiichi Sankyo’s Enhertu should not be made available via the NHS for HER2-low metastatic or unresectable breast cancer after chemotherapy, according to provisional guidance from ...
pharmaphorum7mon
NICE blocks Enhertu use after pricing talks break down
NICE and drugmakers AstraZeneca and Daiichi Sankyo have all expressed their disappointment at being unable to agree on a price for Enhertu that would allow it to be used on the NHS for people with ...
Reuters22d
EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...